Subtle Medical, an AI-powered medical imaging software company, announced it has secured $33 million in growth capital and appointed industry veteran Ohad Arazi as Chief Executive Officer. The financing was anchored by a Series C round led by funds managed by Morgan Stanley Expansion Capital.
The round also included participation from Korea-based Shinhan Venture Investment and existing investors Fusion Fund, EnvisionX, BRV, and Samsung Ventures. With the new financing, Subtle Medical has now raised a total of $86 million.
The company said it will use the funding to accelerate product development, expand commercial adoption globally, and scale its vendor-neutral AI imaging platform across MRI, PET, and CT workflows.
Founded by Enhao Gong, PhD, and Greg Zaharchuk, MD, PhD, Professor of Neuroradiology at Stanford University, Subtle Medical focuses on improving image quality and accelerating scans on existing imaging systems. The company says its AI-powered solutions can reduce scan times by up to 80% and are currently deployed on more than 1,300 scanners worldwide.
As part of the leadership transition, co-founder and former CEO Enhao Gong has moved into the role of Chief Science Officer, where he will oversee the company’s scientific roadmap and continue supporting operations and strategic partnerships in China.
Arazi brings decades of experience in medical imaging and healthcare technology, having held leadership roles at Change Healthcare, Zebra Medical Vision, and Clarius Mobile Health.
Subtle Medical’s flagship products, SubtleHD™ (MR) and SubtlePET™, are used across major imaging networks, academic medical centers, and health systems globally. The company said customers including Mount Sinai Health System, RadNet, and Radiology Partners have reported improvements in throughput, efficiency, and patient experience.
The company is also expanding its AI Imaging Hub platform, which provides health systems with centralized control over imaging performance across MRI, PET, and CT environments regardless of scanner manufacturer. In addition, Subtle Medical is developing SubtleGAD™, a technology designed to enable significantly lower-dose gadolinium-enhanced MRI, with research indicating the potential for up to a 90% reduction in contrast dose while maintaining diagnostic image quality.
KEY QUOTES:
“What drew me to Subtle is that this isn’t a point solution – it’s becoming the AI layer where health systems run their imaging. That’s a fundamentally different kind of company, and a bigger opportunity. I’ve spent my career at the intersection of imaging and enterprise software, and I haven’t seen many platforms with this combination of clinical validation and scalability. I’m here to make sure the world knows about it.”
Ohad Arazi, Chief Executive Officer, Subtle Medical
“Subtle Medical solves a real operational problem for health systems: imaging backlogs that delay care and constrain capacity. We are excited to support Subtle Medical’s next phase of growth to help enhance the patient experience in medical imaging.”
Kevin Han, Executive Director, Morgan Stanley Expansion Capital
“Subtle Medical was founded to make advanced imaging faster, safer, and more accessible. As we enter this next phase, I’m excited to welcome Ohad and continue advancing the science behind our platform while expanding its impact across global imaging workflows.”
Enhao Gong, PhD, Co-Founder And Chief Science Officer, Subtle Medical
